Share
الاستريتين الفموي مقابل غلوكونات الزنك عن طريق الفم : دراسة علاجية مقارنة وعبورية في علاج مرض بهجت == Oral Acitretin Versus Oral Zinc Gluconate As A Comparative Cross - Over Therapeutic Study In Treatment of Behcet,S Disease
Author name:
سناء عبد الحميد حسين
Supervisor name:
هاجر ابراهيم عبد الله | عادل عبد الغفور النعيمي
General topic:
Dentistry
Specific topic:
Oral and Maxillofacial Surgery
Degree:
Master
University:
Mustansiriyah University
Language:
English
University location:
Baghdad
First pages:
20T393 - p.pdf
Abstract:
اساس البحث : مرض بهجت هو اضطراب جهازي حيث ان اسبابه المرضيه ليست محدده جيده.المظاهر الاكثر شيوعا هي الاغشيه المخاطيه الجلديه ولكن يمكن ان يشمل العين, انظمة القلب,الاوعيه الدمويه والجهاز العصبي. هناك العديد من طرائق المعالجه الموضعيه والجهازيه. تمت محاول | Background : Behcet’s disease is a systemic disorder where its etiopathogenesis is not well determined. The commonest manifestations are muccocutaneous but can involve eye, cardiovascular and neurological systems. There are many modalities of therapy topical and systemic.Isotretinion has been tried as an effective therapy of muccocutaneous manifestations. In present work was to try a new retinoid like acitretin which has longer half life than isotretinoin.Aims of the study : To evaluate the effectiveness of oral acitretin versus oral zinc gluconate in the treatment and prophylaxis of Behcet’s disease as a new therapeutic model.Materials and methods : This cross over controlled therapeutic study that conducted in the Department of Dermatology - Baghdad Teaching Hospital the period from August 2013 - May 2014.Twenty patients with fulfilled criteria of Behcets’s disease was included in this work. History and full examination were done for all patients regarding all demo - garaphic points related to the disease. They were given acitretin 25 mg orally once daily for three months to be seen on the day fourteenth firstly and then monthly to be assessed depending on the clinical manifestation index for Behcets disease. After three months, acitretin was stopped and patients were given zinc gluconate 25 mg twice daily for another three months. Results : Twenty patients were treated 12 males (60%), and 8 females (40%), with male to female ratio 1.5 : 1. All these patients completed the study and their ages ranged between 20 - 59 years with mean± SD (37.3±12.3). Pathergy both ordinary and oral were also minimized by this therapy while C - reactive protein was not much effective by this therapy. Zinc gluconate also had the same therapeutic action against these manifestations. Clinical manifestations index before treatment ranged between 1 and 11 with mean ± SD of 5.65±1.98.After acitretin therapy the mean of CMI started to decline to reach 2.65 ±2.03 in first month of the therapy with (p=0.00001) which was statistically high significant and continued high significant till the end of the third month with (p - value > 0.000001). After cessation of acitretin and zinc gluconate started the mean continued to decrease to reach 2.05±2.52 at the end of the first month with (p=<0.000001) which was statistically high significant then; started to increase to reach 3.3 ±2.31 at the end of six month of the therapy but statistically remained high significant (p - value=0.0007). Both acitretin and zinc gluconate have statistically significant effect in reducing severity and frequency of oral ulcers, genital ulcers, skin and rheumatologic manifestations. Conclusions : oral acitretin was found to be an effective therapy in addition to its prophylactic action in treatment of muccocutaneous manifestations of Behcet,s disease. Also zinc gluconate had effective therapeutic action against these features of Behcet’s disease.
